Compound index

Tissue Repair & Cytoprotective Research Peptides

Thymosin beta-4 fragment (17–23)

Also known as TB-500 (ambiguous name) · LKKTETQ

Cell/lab studies onlyNot approved for human use in the US

Last reviewed: 2026-11-19

Overview

A seven-residue fragment of thymosin beta-4; it is not the full 43-residue peptide.

Regulatory status

No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.

    Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

    WADA prohibited status: current list and context

    Evidence at a glance

    Clinical findings for full-length, 43-residue thymosin beta-4 do not establish clinical effects of this seven-residue fragment.

    Key sources

    Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.

    Related compounds

    • BPC-157

      Same scientific class · A 15-amino-acid chain. · Early human trials

    • Thymosin beta-4

      Same scientific class · A 43-amino-acid chain. · Late-stage human trials

    Related glossary terms